Smartlens, Inc. Market Research Report

Company Overview

• Name: Smartlens, Inc.

• Mission: To prevent blindness due to Glaucoma and address the biggest challenges in Glaucoma management, envisioning a world where Glaucoma cannot rob people of their vision and quality of life.

• Founded: No information is available.

• Founders: No information is available.

• Key People: No information is available.

• Headquarters: Mountain View, California.

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known For: Smartlens is known for providing innovative solutions for monitoring and treating Glaucoma through their non-invasive technology.

Products

miLens

• Description: miLens is a first-of-its-kind device that allows continuous monitoring of intraocular pressure (IOP) for Glaucoma patients, anytime and anywhere. The device resembles a daily contact lens and offers significant improvements in managing Glaucoma.

• Key Features:

• Non-invasive and electronics-free.

• Ultra-sensitive.

• Easy-to-use daily contact lens-like design.

• Enables “on the go” IOP monitoring anywhere, at any time.

THERmic

• Description: THERmic applies microdose personalized treatments based on the patient’s diurnal IOP, compatible with all types of Glaucoma medications.

• Key Features:

• Personalized microdose treatments.

• Works with a wide range of Glaucoma medications.

Technologies

• Overview: Smartlens integrates advanced technologies like contact lens manufacturing, microfluidics, and nanofabrication for sensitive IOP measurements. It utilizes imaging software for evaluating conditions via self-photography of patients wearing their lenses.

• Patents: Smartlens holds a portfolio of issued and pending patents in more than 40 countries.

Recent Developments

• New Products: No information is available.

• New Features Added to Existing Products: No information is available.

• Partnerships: The technology is under study at Stanford University for monitoring intracranial pressure (ICP) in neurological disorders and cancers.

Clinical Impact

• Relevance: With more than 140 million people globally suffering from Glaucoma — a number projected to reach 300 million by 2040 — Smartlens provides an efficient way for early diagnosis and monitoring.

• Achievements: Smartlens' miLens contributes to reducing blindness and the economic burden by enabling personalized treatments effectively.

Conclusion

Smartlens, Inc. is positioned as a leader in the innovative care of Glaucoma by offering technology-driven products like miLens and THERmic which specialize in improving patient outcomes through effective monitoring and personalized treatments. With a strong focus on innovation, Smartlens continues to provide essential tools in the fight against Glaucoma-induced blindness.